Source: Annual Congress 2011 - The new clinical spectrum of lung diseases: from bronchi to pleura
Disease area: Airway diseases

Abstract

Background: Eosinophilic bronchitis (EB) is a common cause of chronic cough. Inhaled corticosteroids can improve sputum eosinophilia and cough severity. However, the treatment course with inhaled corticosteroids for EB is unkown.
Objective: To observe the efficacy and recurrence in EB patients with different treatment courses of inhaled corticosteroids.
Methods: 60 patients diagnosised as EB were randomly divided into three groups with inhaled budesonide 200 µg twice daily via a turbohaler for 4 weeks, 8 weeks and 16 weeks respectively. Cough severity was assessed by visual analogue scale (VAS) and daytime cough symptom score at baseline and during the treatment period. Airway inflamation was assessed by sputum eosinophil count (Eos%). All the patients were followed up for 6 months after treatment.
Results: The daytime cough score after treatment decreased in all three group (p<0.05), which was lower in 16 weeks group and 8 weeks group than 4 weeks group (p<0.05). The rate that VAS decreased over 80% after treatment were 55% in 4 weeks group, lower than 8 weeks, 16 weeks group (85%, 95%, p<0.05). The sputum eosinophil count decreased in all three group after treatment. The rate that sputum eosinophil count returned to normal level (Eos%<2.5%) in 8 weeks group (75%), 16 weeks group (95%) were significantly higher than 4 weeks group (50%, p<0.05). The rate of recurrence was 31.3%, 23.5%, 27.8% in 4, 8, 16 weeks group respectively. There are no significant difference among three groups.
Conclusion: Our results suggest that eosinophilic brochitis should be treated with low-dose inhaled budesonide for over 8 weeks. Recurrence appear not to be related to treatment course.

Rating:

Share or cite this content

Citations should be made in the following way:
K. Lai, D. Xu, J. Xie, W. Luo, N. Zhong (Guangzhou, China). Different treatment courses with inhaled corticosteroids for eosinophilic bronchitis. Eur Respir J 2011; 38: Suppl. 55, 483

Member's Comments

No comment yet.

Related content which might interest you: Response to inhaled corticosteroids in patients with non-asthmatic eosinophilic bronchitis Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 Inhaled corticosteroids in the treatment of acute asthma Source: Eur Respir J 2002; 20: Suppl. 38, 305s Year: 2002 Efficacy of systemic corticosteroids in refractory asthmatics showing no bronchial reversibility with high-dose inhaled corticosteroids or β2 agonist inhalation Source: Annual Congress 2010 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2010 Effects of inhaled corticosteroids on cough in asthma patients Source: Eur Respir J 2004; 24: Suppl. 48, 347s Year: 2004 An economic evaluation of adding inhaled corticosteroids to systemic corticosteroids for treating acute asthma exacerbations Source: International Congress 2019 – Severe acute asthma and troublesome wheezing Year: 2019 Exacerbations and inhaled corticosteroids in bronchiectasis patients Source: International Congress 2019 – Phenotypes and endotypes of bronchiectasis Year: 2019 The effect of inhaled lidocaine-hydrofluoroalkane 134a in prednisone-dependent eosinophilic bronchitis Source: Eur Respir J 2008; 32: 1119-1122 Year: 2008 Utility of aerosolized budesonide therapy in acute moderate exacerbations of asthma Source: Eur Respir J 2003; 22: Suppl. 45, 283s Year: 2003 Effects of montelukast on tapering inhaled corticosteroids in patients with asthma Source: Eur Respir J 2001; 18: Suppl. 33, 260s Year: 2001 Effects of montelukast on tapering inhaled corticosteroids in patients with asthma Source: Eur Respir J 2002; 20: Suppl. 38, 407s Year: 2002 Comparison of oral prednisolone and nebulized budesonide in the treatment of acute exacerbations of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 214s Year: 2001 Comparison of inhaled corticosteroid combined with theophylline and double-dose inhaled corticosteroid in moderate-severe persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 127s Year: 2004 Adding slow-released theophyllne to inhaled corticosteroids in the treatment of mild persistent asthma Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007 Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment Source: Eur Respir J 2006; 27: 964-971 Year: 2006 Montelukast plus inhaled budesonide versus double dose inhaled budesonide in nonasthmatic eosinophilic bronchitis Source: Annual Congress 2011 - Asthma: control and treatment Year: 2011 Aerosolized budesonide therapy in acute moderate exacerbations of Indian asthmatics Source: Eur Respir J 2004; 24: Suppl. 48, 343s Year: 2004 Airway autoimmunity and response to a 14-day course of oral corticosteroids in patients with severe eosinophilic asthma Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma Year: 2020 Risks of pneumonia in asthmatic patients taking inhaled corticosteroids Source: Annual Congress 2010 - Management of airway disease Year: 2010 Cough variant asthma treated with bronchodilators, without inhaled corticosteroids Source: Annual Congress 2009 - From cough to sound analysis of breathing Year: 2009 Oral corticosteroids in the treatment of exacerbation of severe asthma Source: Virtual Congress 2020 – Exhaled biomarkers of asthma and the asthma burden Year: 2020